CG Oncology, Inc. (CGON) AI Stock Analysis

• Market Cap: $5.56B
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: 217.84%
• EPS Growth: -85.53%
• Country: US
• Employees: 113
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.55
• Shares Outstanding: 84,435,200
• 10 Day Avg. Volume: 1,679,807
• 30 Day Avg. Volume: 1,077,976
• PEG Ratio: -0.42
• Price to Book (P/B): 4.26
• Price to Sales (P/S): 794.47
• P/FCF Ratio: -24.23
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 1.37K
• Enterprise Value/Gross Profit: -9.12K
• Enterprise Value/Ebitda: -33.11
• 1Y Price Target: $83.91
• Price Target Upside: 30.52% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): -2.35
• Revenue Forecast (FY): $21.54M

• Rating: 61 Neutral
• Price Target: $62.00 ▼(-3.56% Downside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is driven primarily by weak profitability and heavy cash burn despite strong balance-sheet flexibility, partially offset by favorable technical momentum and a positive Phase 3 timeline acceleration. Traditional valuation metrics provide limited support due to ongoing losses.

Positive Factors

Strong cash runway

A cash balance near $903M and stated runway into H1 2029 materially reduces near-term financing pressure. This durability allows CG Oncology to complete Phase 3 readout activities, invest in regulatory/commercial preparations, and pursue partnerships without immediate dilution risk.

Very low leverage

Near-zero leverage gives the company financial flexibility to fund R&D, absorb clinical setbacks, or pursue M&A without high interest burdens. A strong equity base supports long-term strategic choices and reduces solvency risk while clinical programs advance.

Accelerated registrational Phase 3

An expedited Phase 3 readout and being the first registrational randomized trial in this indication creates a potential first-mover and regulatory advantage. Positive results could establish a new standard in a large unmet market and materially strengthen long-term commercial prospects.

Negative Factors

Significant and rising cash burn

Rapidly increasing operating cash outflows indicate high ongoing spend to support trials and operations. Even with current cash, sustained burn raises the probability of future financings or cutbacks if product milestones slip, constraining strategic optionality over time.

Deep unprofitability and negative gross profit

Large net losses and negative gross profit show current operations are not yet economically scalable. Long-term value depends on successful commercialization; until then, returns on equity are negative and sustained losses could erode shareholder value.

Equity financing and dilution risk

The enlarged ATM program and recent ATM sales signal dependence on equity markets to fund operations. While providing flexibility, continued issuance can dilute existing shareholders and represents ongoing financing risk if clinical or commercial milestones are delayed.

CG Oncology, Inc. Business Overview & Revenue Model

Company Description

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

How the Company Makes Money

CG Oncology generates revenue primarily through the development and commercialization of its cancer therapies. The company may receive funding through partnerships and collaborations with larger pharmaceutical firms, which often involve milestone payments and royalties on future sales of approved products. Additionally, CGON may obtain revenue from government grants or research funding aimed at advancing its clinical trials. As the company progresses through the stages of drug development, it has the potential to generate significant earnings from product sales once its therapies are approved by regulatory bodies and launched into the market.

CG Oncology, Inc. Financial Statement Overview

Summary

Mixed fundamentals: revenue accelerated sharply ($4.0M in 2025 vs. $1.1M in 2024) and leverage is extremely low (debt-to-equity ~0.01) with a large equity base (~$752.6M). However, the company remains deeply unprofitable (2025 net loss ~$161.0M), gross profit turned negative, and cash burn is large and rising (operating cash flow about -$132.3M in 2025), which is the main constraint on the score.

Income Statement

Revenue has accelerated sharply in the most recent annual period ($4.0M in 2025 vs. $1.1M in 2024), but the business remains deeply unprofitable with very large operating and net losses (2025 net loss of ~$161.0M). Profitability deteriorated materially in 2025, with gross profit turning negative and losses expanding much faster than revenue, indicating heavy spend and weak operating leverage at the current scale.

Balance Sheet

The balance sheet is a clear strength: leverage is extremely low (2025 debt-to-equity ~0.01) and equity is substantial (~$752.6M) relative to total assets (~$791.6M), providing financial flexibility. The key weakness is ongoing negative returns on equity driven by large losses (2025 return on equity ~-0.21), which can pressure the equity base over time if losses persist.

Cash Flow

Cash burn is significant and rising: operating cash flow was about -$132.3M in 2025 (vs. -$78.7M in 2024), and free cash flow was similarly negative (~-132.5M). A positive point is that free cash flow broadly tracks net loss (free cash flow to net income ~1.0 across periods), suggesting losses largely translate into cash usage rather than being masked by accounting items; however, the magnitude of burn remains the central risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.04M	1.14M	204.00K	191.00K	10.36M
Gross Profit	-607.00K	1.14M	204.00K	176.00K	10.35M
EBITDA	-159.55M	-114.63M	-55.43M	-35.23M	-12.38M
Net Income	-161.00M	-88.04M	-48.61M	-35.44M	-12.84M
Balance Sheet
Total Assets	791.59M	754.80M	199.30M	147.75M	58.69M
Cash, Cash Equivalents and Short-Term Investments	742.15M	742.00M	187.67M	143.48M	53.61M
Total Debt	7.02M	238.00K	1.03M	15.94M	15.13M
Total Liabilities	38.99M	21.42M	14.51M	22.57M	18.44M
Stockholders Equity	752.60M	733.38M	184.79M	125.18M	40.25M
Cash Flow
Free Cash Flow	-132.48M	-78.95M	-45.68M	-29.82M	-13.75M
Operating Cash Flow	-132.35M	-78.71M	-45.68M	-29.80M	-13.65M
Investing Cash Flow	-245.82M	-300.76M	-121.19M	-55.35M	-97.00K
Financing Cash Flow	153.59M	628.28M	87.00M	119.69M	15.45M

CG Oncology, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 64.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Positive. The current price of 64.29 is above the 20-day moving average (MA) of 59.79, above the 50-day MA of 54.69, and above the 200-day MA of 39.11, indicating a bullish trend. The MACD of 3.10 indicates Negative momentum. The RSI at 69.37 is Neutral, neither overbought nor oversold. The STOCH value of 88.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGON.

CG Oncology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	63 Neutral	$2.82B	-228.91	-10.26%	―	129.21%	80.35%
CGON	61 Neutral	$5.56B	-19.94	-22.87%	―	217.84%	-85.53%
BEAM	54 Neutral	$2.60B	-34.27	-7.31%	―	-84.07%	-157.71%
IDYA	52 Neutral	$3.06B	―	-11.10%	―	5376.27%	20.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COGT	49 Neutral	$5.79B	-7.30	-100.22%	―	―	4.32%
IRON	43 Neutral	$2.29B	―	-32.80%	―	―	-34.96%

CG Oncology, Inc. Corporate Events

CG Oncology Expands At-The-Market Equity Offering Capacity

On January 13, 2026, CG Oncology, Inc. filed an amended prospectus with the U.S. Securities and Exchange Commission to expand its existing open market stock offering program with Jefferies LLC, increasing the total aggregate offering capacity from $250 million to up to $550 million of common stock. The company had previously sold 5,861,984 shares for gross proceeds of $250 million under this sales agreement and is now seeking to raise an additional $300 million, a move that significantly enlarges its potential capital-raising runway and could support future corporate financing needs and strategic initiatives while diluting existing shareholders if fully utilized.

The most recent analyst rating on (CGON) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline

On January 9, 2026, CG Oncology announced that topline data from its Phase 3 PIVOT-006 trial of adjuvant intravesical cretostimogene grenadenorepvec in intermediate-risk non-muscle invasive bladder cancer are now expected in the first half of 2026, nearly a year earlier than originally planned, following rapid enrollment of more than 360 patients across over 90 sites. The company highlighted that PIVOT-006 is the first randomized Phase 3 registrational study in this underserved patient group, which is estimated to exceed 50,000 individuals in the U.S., and the accelerated timeline, alongside encouraging safety and efficacy signals from the BOND-003 and CORE-008 studies reported as of September 1, 2025, underscores cretostimogene’s potential to reshape the treatment landscape for NMIBC and could materially strengthen CG Oncology’s position in bladder cancer therapeutics if future results remain favorable.

The most recent analyst rating on (CGON) stock is a Buy with a $89.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.